The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress
Platinum chemotherapies are highly effective cytotoxic agents but often induce resistance when used as monotherapies. Combinatorial strategies limit this risk and provide effective treatment options for many cancers. Here, we repurpose atovaquone (ATQ), a well-tolerated & FDA-approved anti-malar...
Auteurs principaux: | Coates, JTT, Rodriguez-Berriguete, G, Puliyadi, R, Ashton, T, Prevo, R, Wing, A, Granata, G, Pirovano, G, McKenna, GW, Higgins, GS |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Springer Nature
2020
|
Sujets: |
Documents similaires
-
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
par: Ashton, T, et autres
Publié: (2016) -
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
par: Thomas M. Ashton, et autres
Publié: (2016-07-01) -
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner
par: Prevo, R, et autres
Publié: (2018) -
Investigating the role of the anti-malarial drug Atovaquone in anti-cancer therapy
par: Watson, D, et autres
Publié: (2019) -
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models
par: Gonzalo Rodriguez-Berriguete, et autres
Publié: (2024-01-01)